Paola Molino - Profile on Academia.edu (original) (raw)
Related Authors
Uploads
Papers by Paola Molino
Journal of Human Hypertension, 1999
Autonomic nervous dysfunction, such as parasympathetic and sympathetic impairment, has been sugge... more Autonomic nervous dysfunction, such as parasympathetic and sympathetic impairment, has been suggested as possible cause of pre-eclampsia, but the studies are not conclusive. Our purpose was to assess non-invasively if pre-eclampsia is associated with a decreased baroreflex function. Nine women with pre-eclampsia (PE), eight normotensive pregnant women, and seven healthy normotensive non-pregnant women were studied. Continuous finger blood pressure was recorded by a Portapres device in the left lateral recumbent position and active standing. Baroreflex gain was evaluated by
American Journal of Hypertension, 1995
Carvedilol (CA) is a new antihypertensive agent with combined non-selective beta-blocking and vas... more Carvedilol (CA) is a new antihypertensive agent with combined non-selective beta-blocking and vasodilatatory actions. AIm: to compare the effects of CA with Atenolol (A). a selective beta·blocker. on diurnal BP profile In mild· moderate essential hypertensives. Metho!fs: 30 patients (pts) were studied. After a 2 weeks run in period, they were randomly assigned to A 50-100 mg, or CA25-50 mg.
Journal of Human Hypertension, 1999
Autonomic nervous dysfunction, such as parasympathetic and sympathetic impairment, has been sugge... more Autonomic nervous dysfunction, such as parasympathetic and sympathetic impairment, has been suggested as possible cause of pre-eclampsia, but the studies are not conclusive. Our purpose was to assess non-invasively if pre-eclampsia is associated with a decreased baroreflex function. Nine women with pre-eclampsia (PE), eight normotensive pregnant women, and seven healthy normotensive non-pregnant women were studied. Continuous finger blood pressure was recorded by a Portapres device in the left lateral recumbent position and active standing. Baroreflex gain was evaluated by
American Journal of Hypertension, 1995
Carvedilol (CA) is a new antihypertensive agent with combined non-selective beta-blocking and vas... more Carvedilol (CA) is a new antihypertensive agent with combined non-selective beta-blocking and vasodilatatory actions. AIm: to compare the effects of CA with Atenolol (A). a selective beta·blocker. on diurnal BP profile In mild· moderate essential hypertensives. Metho!fs: 30 patients (pts) were studied. After a 2 weeks run in period, they were randomly assigned to A 50-100 mg, or CA25-50 mg.